Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Rapid Micro Biosystems, Inc.

RPIDNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jun 2, 2026Accepted Jun 2, 2026, 7:42 PM EDTFiling CIK 1380106Accession 0001326794-26-000007
Share

Structured filing — 4

wk-form4_1780443754.xml

Open full document ↗

Filing details

Report period
2026-05-29
Issuer
RAPID MICRO BIOSYSTEMS, INC.
Issuer CIK
0001380106
Trading symbol
RPID

Reporting owner 1

Name
Malloy Kirk
Reporting owner CIK
0001326794
Relationship
Director
Address
C/O RAPID MICRO BIOSYSTEMS, INC., 25 HARTWELL AVENUE, LEXINGTON, MA, 02421

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Class A Common Stock2026-05-29A · Form 4[F1]12,787A1.95560,687D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnershipNature of ownership
Class A Common Stock10,000IBy Trust[F2]
Table key
I
Indirect

Derivative transactions

Derivative transactions · 2 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Series A Warrant (right to buy)1.9552026-05-29A · Form 4[F1]12,787A0[F1]2026-11-29[F3]2027-05-29Class A Common Stock12,78712,787D
Series B Warrant (right to buy)2.342026-05-29A · Form 4[F1]12,787A0[F1]2026-11-29[F3]2031-05-29Class A Common Stock12,78712,787D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.↩ 1↩ 2↩ 3↩ 4↩ 5
F2
Shares held in family trust as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.↩ 1
F3
The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.↩ 1↩ 2

Signature 1

Signed
/s/ Sean M. Wirtjes, Attorney-in-Fact for Kirk Malloy
Date
2026-06-02

Company context

Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Current securities

Recent company filings

  1. 10-Q filingNov 19, 2026
  2. SC14D9C - filed by RAPID MICRO BIOSYSTEMS, INC. regarding RAPID MICRO BIOSYSTEMS, INC.Nov 17, 2026
  3. NT 10-Q filingNov 16, 2026
  4. SC14D9C - filed by RAPID MICRO BIOSYSTEMS, INC. regarding RAPID MICRO BIOSYSTEMS, INC.Nov 16, 2026
  5. Entry into a Material Definitive Agreement · Other EventsNov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.